Press Releases

Bolt Biotherapeutics Closes $93.5 Million Series C Financing ...
Read More

Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody™ ISAC Technology and its Lead Development Candidate, BDC-1001 ...
Read More

Bolt Biotherapeutics Appoints William P. Quinn as Chief Financial Officer ...
Read More

Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer ...
Read More

Bolt Biotherapeutics Appoints Nathan Ihle, Ph.D., as Vice President of CMC and Quality ...
Read More

Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors ...
Read More

Bolt Biotherapeutics Appoints Dr. Nils Lonberg to its Scientific Advisory Board ...
Read More

Bolt Biotherapeutics Expands Scientific Advisory Board with Appointment of Dr. Priti Hegde ...
Read More

Bolt Biotherapeutics Presents Data At SITC Conference Showing Eradication of Large Tumors in Preclinical Studies ...
Read More

Media Coverage

Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs Xconomy ...
Read More

Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement ADC Review ...
Read More

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001 ADC Review ...
Read More

Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics ADC Review ...
Read More

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy ADC Review ...
Read More

Bolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor's New Idea Deeper in the Clinic Endpoints News ...
Read More

Bolt’s Myeloid Twist on ADCs Charged up with $93.5M series C BioCentury ...
Read More

Pfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med Hits the Clinic Fierce Biotech ...
Read More

Agonist ecstasy? HER2 (and more) ‘Bolt’-on strategy draws $93.5M series C BioWorld ...
Read More

Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors Precision Oncology News ...
Read More

Podcasts

Randy Schatzman, PhD, CEO of Bolt Biotherapeutics Biotech 2050 Podcast ...
Listen Now

Advances in Targeted Cancer Therapy with Dr. Edith Perez Empowered Patient Podcast ...
Listen Now

Posters & Publications

HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner Presented at: 2019 Society for Immunotherapy of Cancer (SITC) ...
Read More

TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity Presented at: 2019 American Association for Cancer Research (AACR) ...
Read More

Systemic Immunity is Required for Effective Cancer Immunotherapy Spitzer MH, et al. Cell (2017) ...
Read More

Allogenic IgG Combined with Dendritic Cell Stimuli Induce Antitumor T-cell Immunity Carmi Y, et al. Nature (2015) ...
Read More